Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness

George F. Widhopf II, Emanuela M. Ghia, Matthew R. Cring, Thomas J. Kipps

Blood (2024) 144 (Supplement 1): 744.

https://doi.org/10.1182/blood-2024-210584

Published: 2024

Journal Articles

ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)

Emanuela M. Ghia, Michael Y. Choi, George F. Widhopf II, Thomas J. Kipps

Blood (2024) 144 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2024-211735

Published: 2024

Journal Articles

Defining Signaling Interactomes Involved in Non-Canonical Wnt Signaling By ROR1 or ROR2 in Hairy Cell Leukemia That Can Influence Cell Morphology and Migration

Matthew Cring, George Widhopf, Emanuela M. Ghia, Thomas J. Kipps

Blood (2023) 142 (Supplement 1): 4378.

https://doi.org/10.1182/blood-2023-189562

Published: 2023

Journal Articles

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Miguel Quijada Álamo, Laura Z. Rassenti, Emanuela M. Ghia, Tuan Tran, Monica Spydell, Elsa Molina, Claudia Pérez Carretero, Luis A. Corchete, Teresa González, Jesús María Hernández-Rivas, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 4113–4114.

https://doi.org/10.1182/blood-2022-166403

Published: 2022

Journal Articles

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Larissa Balaian, Mary Donohoe, Phoebe Mondala, George F. Widhopf II, Emanuela M. Ghia, Edward D. Ball, Anna Kulidjian, Inge Van Der Werf, Thomas J. Kipps, Catriona Jamieson

Blood (2022) 140 (Supplement 1): 3356–3357.

https://doi.org/10.1182/blood-2022-170128

Published: 2022

Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-134711

Published: 2020

Journal Articles

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Laura Z. Rassenti, PhD, Michael Y. Choi, MD, Elvin Chu, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 476.

https://doi.org/10.1182/blood-2019-131426

Published: 2019

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Yun Chen, Liguang Chen, Jian Yu, Emanuela M. Ghia, Michael Y. Choi, Ling Zhang, Suping Zhang, Elsa Sanchez-Lopez, George F. Widhopf, II, Karen Messer, Laura Z. Rassenti, Catriona Jamieson, Thomas J. Kipps

Blood (2019) 134 (13): 1084–1094.

https://doi.org/10.1182/blood.2019001366

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia

Emanuela M. Ghia, Laura Z. Rassenti, Donna S. Neuberg, Alejandro Blanco, Fouad Yousif, Erin N. Smith, John D. McPherson, Thomas J. Hudson, the HALT Pan-Leukemia Gene Panel Consortium, Olivier Harismendy, Kelly A. Frazer, Thomas J. Kipps

Blood (2019) 133 (25): 2651–2663.

https://doi.org/10.1182/blood-2018-09-873695

Published: 2019

Includes: Supplemental data

Journal Articles

Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia

Christina Wu, PhD, Emanuela M. Ghia, PhD, Fitzgerald Lao, Minya Pu, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Dennis A. Carson, MD, Michael Y. Choi, MD

Blood (2018) 132 (Supplement 1): 3143.

https://doi.org/10.1182/blood-2018-99-119292

Published: 2018

Journal Articles

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Han Zhang, PhD, Suping Zhang, PhD, Emanuela M. Ghia, PhD, Michael Y. Choi, MD, Jieyu Zhang, MS, Liguang Chen, PhD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 2652.

https://doi.org/10.1182/blood-2018-99-119606

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

Journal Articles

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Michael Y. Choi, MD, George F. Widhopf II, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD

Blood (2018) 132 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2018-99-119711

Published: 2018

Journal Articles

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Elsa Sanchez-Lopez, PhD, Emanuela M. Ghia, PhD, Laura Antonucci, PhD, Laura Z. Rassenti, PhD, Yun Chen, PhD, Thomas J. Kipps, MD PhD, Michael Karin, PhD

Blood (2018) 132 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2018-99-115564

Published: 2018

Journal Articles

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

Blood (2017) 130 (Supplement 1): 264.

https://doi.org/10.1182/blood.V130.Suppl_1.264.264

Published: 2017

Journal Articles

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

Bing Cui, Emanuela M. Ghia, Liguang Chen, Laura Z. Rassenti, Christopher DeBoever, George F. Widhopf, II, Jian Yu, Donna S. Neuberg, William G. Wierda, Kanti R. Rai, Neil E. Kay, Jennifer R. Brown, Jeffrey A. Jones, John G. Gribben, Kelly A. Frazer, Thomas J. Kipps

Blood (2016) 128 (25): 2931–2940.

https://doi.org/10.1182/blood-2016-04-712562

Published: 2016

Includes: Supplemental data

Journal Articles

Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

Jean Fan, BS, Lili Wang, MD PhD, Angela N Brooks, PhD, Youzhong Wan, PhD, Donna S Neuberg, ScD, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD, PhD, Jennifer R. Brown, MD PhD, Shuqiang Li, Kenneth J Livak, Matthew M. Meyerson, PhD, Peter V. Kharchenko, PhD, Catherine J. Wu, MD

Blood (2015) 126 (23): 2906.

https://doi.org/10.1182/blood.V126.23.2906.2906

Published: 2015

Journal Articles

High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia

Bing Cui, PhD, Liguang Chen, MD PhD, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Jian Yu, PhD, Ling Zhang, PhD, Donna S Neuberg, ScD, William Wierda, MD PhD, Michael Keating, MBBS, Kanti R. Rai, MD, Neil E. Kay, MD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, John Gribben, MDDSc, Thomas J. Kipps, MD, PhD

Blood (2015) 126 (23): 1713.

https://doi.org/10.1182/blood.V126.23.1713.1713

Published: 2015

NARROW

Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness

ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)

Defining Signaling Interactomes Involved in Non-Canonical Wnt Signaling By ROR1 or ROR2 in Hairy Cell Leukemia That Can Influence Cell Morphology and Migration

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia

Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia

Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia

Cirmtuzumab Inhibits Non-Canonical Wnt Signaling without Enhancing Canonical Wnt/β-Catenin Signaling in Chronic Lymphocytic Leukemia

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only